NOVOCURE LTD
NVCRNASDAQTrading Snapshot
- Day Range
- $15.86 – $16.30
- 52-Week Range
- $9.82 – $21.45
- Volume
- $2.65B
- Avg Volume
- $2.93B
- Shares Outstanding
- 116.5M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $655M
- Last Q Revenue
- $184M
- P/E Ratio
- —
- P/S Ratio
- 2.6x
- EPS (TTM)
- $-1.31
- Dividend Yield
- —
- Dilution (1yr)
- +3.4%
Why Investors Own NVCR
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NOVOCURE LTD
NVCR
StockOtter · stockotter.spaceAbout NOVOCURE LTD
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
NovoCure Limited $NVCR Stake Trimmed by Corient Private Wealth LP
Corient Private Wealth LP lessened its holdings in NovoCure Limited (NASDAQ: NVCR) by 71.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Confe
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Novocure Announces Upcoming Investor Events
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonar
Oncology firm Novocure says cyberattack exposed US patient records
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patients.